Literature DB >> 18796266

Status of immune mediators in fibromyalgia.

Ali Gur1, Pelin Oktayoglu.   

Abstract

Fibromyalgia (FM) is a form of nonarticular rheumatism characterized by long-term (> 3 months) and widespread musculoskeletal pain. However, the biophysiology of FM has remained elusive, and the treatment remains mainly empirical. There are numerous hypotheses about the pathophysiology of chronic widespread pain and FM; one includes a possible role of cytokines. Cytokines play a role in diverse clinical processes and phenomena such as fatigue, fever, sleep, pain, stress, and aching. Cytokines related to acute or repetitive tissue injuries may be responsible for long-term activation of spinal cord glia and dorsal horn neurons, thus resulting in central sensitization. Pain, stiffness, and depression in FM could be associated with some signs of inflammatory response system activation. Illumination of the pathophysiologic secrets of FM will result in more effective treatment regimens. We review the role of immune mediators in the pathophysiology of FM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18796266     DOI: 10.1007/s11916-008-0031-4

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  59 in total

Review 1.  Neurochemical pathogenesis of fibromyalgia.

Authors:  I J Russell
Journal:  Z Rheumatol       Date:  1998       Impact factor: 1.372

Review 2.  Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions.

Authors:  J M Mullington; D Hinze-Selch; T Pollmächer
Journal:  Ann N Y Acad Sci       Date:  2001-03       Impact factor: 5.691

Review 3.  Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness.

Authors:  Shawn Hayley; Zul Merali; Hymie Anisman
Journal:  Stress       Date:  2003-03       Impact factor: 3.493

4.  Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Authors:  Henning Vaerøy; Robert Helle; Øystein Førre; Erik Kåss; Lars Terenius
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

Review 5.  Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin.

Authors:  C A Nichol; G K Smith; D S Duch
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

6.  Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome.

Authors:  N Hader; D Rimon; A Kinarty; N Lahat
Journal:  Arthritis Rheum       Date:  1991-07

7.  IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction.

Authors:  N Buchs; T Silvestri; F S di Giovine; M Chabaud; E Vannier; G W Duff; P Miossec
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

Review 8.  Syndromes of glucocorticoid resistance.

Authors:  G P Chrousos; S D Detera-Wadleigh; M Karl
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

9.  Intracerebroventricular injection of isoproterenol produces its analgesic effect through interleukin-1beta production.

Authors:  K Yabuuchi; E Maruta; J Yamamoto; A Nishiyori; S Takami; M Minami; M Satoh
Journal:  Eur J Pharmacol       Date:  1997-09-10       Impact factor: 4.432

Review 10.  Mechanisms of pain in arthritis.

Authors:  Hans-Georg Schaible; Andrea Ebersberger; Gisela Segond Von Banchet
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

View more
  13 in total

Review 1.  Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

2.  Helicobacter pylori seropositivity in fibromyalgia syndrome.

Authors:  Nuray Akkaya; Semih Akkaya; Yusuf Polat; Meral Turk; Tufan Turk; Elif Turhal; Fusun Sahin
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

3.  Dynamic interactions between plasma IL-1 family cytokines and central endogenous opioid neurotransmitter function in humans.

Authors:  Alan R Prossin; Steven S Zalcman; Mary M Heitzeg; Alisa E Koch; Phillip L Campbell; K Luan Phan; Christian S Stohler; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-08-20       Impact factor: 7.853

4.  Non-invasive brain stimulation approaches to fibromyalgia pain.

Authors:  Baron Short; Jeffrey J Borckardt; Mark George; Will Beam; Scott T Reeves
Journal:  J Pain Manag       Date:  2009-01-01

5.  Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index.

Authors:  Maria E Hernandez; Enrique Becerril; Mayra Perez; Philippe Leff; Benito Anton; Sergio Estrada; Iris Estrada; Manuel Sarasa; Enrique Serrano; Lenin Pavon
Journal:  BMC Res Notes       Date:  2010-06-03

6.  Effects of guided imagery on biobehavioral factors in women with fibromyalgia.

Authors:  Victoria Menzies; Debra E Lyon; R K Elswick; Nancy L McCain; D Patricia Gray
Journal:  J Behav Med       Date:  2014-02

7.  Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.

Authors:  Joanna Leaviss; Sarah Davis; Shijie Ren; Jean Hamilton; Alison Scope; Andrew Booth; Anthea Sutton; Glenys Parry; Marta Buszewicz; Rona Moss-Morris; Peter White
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

Review 8.  Biomarkers in fibromyalgia.

Authors:  Jacob N Ablin; Dan Buskila; Daniel J Clauw
Journal:  Curr Pain Headache Rep       Date:  2009-10

Review 9.  Systematic review with meta-analysis: cytokines in fibromyalgia syndrome.

Authors:  Nurcan Uçeyler; Winfried Häuser; Claudia Sommer
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362

10.  Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement.

Authors:  Mario D Cordero; Francisco Javier Cano-García; Elísabet Alcocer-Gómez; Manuel De Miguel; José Antonio Sánchez-Alcázar
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.